Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $6.6 million.

  • Exagen's Other Non-Current Liabilities rose 348594.59% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 348594.59%. This contributed to the annual value of $357000.0 for FY2023, which is 5882.35% down from last year.
  • As of Q3 2025, Exagen's Other Non-Current Liabilities stood at $6.6 million, which was up 348594.59% from $4.0 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Other Non-Current Liabilities peaked at $6.6 million during Q3 2025, and registered a low of $122000.0 during Q1 2025.
  • Over the past 5 years, Exagen's median Other Non-Current Liabilities value was $786500.0 (recorded in 2022), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Exagen's Other Non-Current Liabilities tumbled by 6331.66% in 2024, and later surged by 348594.59% in 2025.
  • Exagen's Other Non-Current Liabilities (Quarter) stood at $1.4 million in 2021, then tumbled by 38.38% to $867000.0 in 2022, then plummeted by 58.82% to $357000.0 in 2023, then plummeted by 48.18% to $185000.0 in 2024, then surged by 3485.95% to $6.6 million in 2025.
  • Its last three reported values are $6.6 million in Q3 2025, $4.0 million for Q2 2025, and $122000.0 during Q1 2025.